Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider

INTRODUCTION: Despite a large number of trials, the role of bevacizumab (BEV) in the treatment of recurrent high-grade gliomas is still controversial. Evidence regarding an effect on overall survival in this context is ultimately inconclusive. At the Department of Radiation Oncology at Erlangen, Ger...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Susanne, Schmidt, Manuel Alexander, Weissmann, Thomas, Eyüpoglu, Ilker, Strnad, Annedore, Semrau, Sabine, Fietkau, Rainer, Putz, Florian, Lettmaier, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316675/
https://www.ncbi.nlm.nih.gov/pubmed/32409944
http://dx.doi.org/10.1007/s11060-020-03533-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316675/
https://www.ncbi.nlm.nih.gov/pubmed/32409944
http://dx.doi.org/10.1007/s11060-020-03533-5

Ejemplares similares